The DOI matches its Crossref record; 641 of the 641 references it cites were found in a registry or an index.
The Treatment of Cushing's Disease
Open accessAbstract
Cushing's disease (CD), or pituitary-dependent Cushing's syndrome, is a severe endocrine disease caused by a corticotroph pituitary tumor and associated with increased morbidity and mortality. The first-line treatment for CD is pituitary surgery, which is followed by disease remission in around 78% and relapse in around 13% of patients during the 10-year period after surgery, so that nearly one third of patients experience in the long-term a failure of surgery and require an additional second-line treatment. Patients with persistent or recurrent CD require additional treatments, including pituitary radiotherapy, adrenal surgery, and/or medical therapy. Pituitary radiotherapy is effective in controlling cortisol excess in a large percentage of patients, but it is associated with a considerable risk of hypopituitarism. Adrenal surgery is followed by a rapid and definitive control of cortisol excess in nearly all patients, but it induces adrenal insufficiency. Medical therapy has recently acquired a more important role compared to the past, due to the recent employment of novel compounds able to control cortisol secretion or action. Currently, medical therapy is used as a presurgical treatment, particularly for severe disease; or as postsurgical treatment, in cases of failure or incomplete surgical tumor resection; or as bridging therapy before, during, and after radiotherapy while waiting for disease control; or, in selected cases, as primary therapy, mainly when surgery is not an option. The adrenal-directed drug ketoconazole is the most commonly used drug, mainly because of its rapid action, whereas the glucocorticoid receptor antagonist, mifepristone, is highly effective in controlling clinical comorbidities, mainly glucose intolerance, thus being a useful treatment for CD when it is associated with diabetes mellitus. Pituitary-directed drugs have the advantage of acting at the site responsible for CD, the pituitary tumor. Among this group of drugs, the dopamine agonist cabergoline and the somatostatin analog pasireotide result in disease remission in a consistent subgroup of patients with CD. Recently, pasireotide has been approved for the treatment of CD when surgery has failed or when surgery is not an option, and mifepristone has been approved for the treatment of Cushing's syndrome when associated with impairment of glucose metabolism in case of the lack of a surgical indication. Recent experience suggests that the combination of different drugs may be able to control cortisol excess in a great majority of patients with CD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 401–600 of 641
Pediatric pituitary adenoma: a series of 42 patients
Pandey, P., Ojha, B. K., & Mahapatra, A. K. (2005) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2004.10.003 · Cited by 69
Somatostatin: A potent inhibitor of ACTH-Hypersecretion in adrenal insufficiency
Fehm, H., Voigt, K. H., Lang, R., Beinert, K. E., Raptis, S., & Pfeiffer, E. F. (1976) · Journal of Molecular Medicine · doi:10.1007/bf01468882 · Cited by 68
Factors Associated With Endocrine Deficits After Stereotactic Radiosurgery of Pituitary Adenomas
Leenstra, J. L., Tanaka, S., Kline, R. W., Brown, P. D., Link, M. J., Nippoldt, T. B., Young, W. F., & Pollock, B. E. (2010) · Neurosurgery · doi:10.1227/01.neu.0000370978.31405.a9 · Cited by 68
Fomekong, E., Maiter, D. M., Grandin, C. B. G., & Raftopoulos, C. (2009) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2008.12.011 · Cited by 68
Biochemical Predictors of Outcome of Pituitary Surgery for Cushing’s Disease
Alwani, R. A., de Herder, W. W., van Aken, M. O., Berge, J., Delwel, E. J., Dallenga, A. H. G., de Jong, F. H., Lamberts, S. W. J., van der Lely, A. J., & Feelders, R. A. (2009) · Neuroendocrinology · doi:10.1159/000258677 · Cited by 68
Desmopressin stimulation test before and after pituitary surgery in patients with Cushing's disease
Losa, M., Mortini, P., Dylgjeri, S., Barzaghi, L. R., Franzin, A., Mandelli, C., & Giovanelli, M. A. (2001) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2001.01324.x · Cited by 67
Albiger, N. M. E., Testa, R., Almoto, B., Ferrari, M., Bilora, F., Petrobelli, F., Pagnan, A., Mantero, F., & Scaroni, C. M. (2006) · Hormone and Metabolic Research · doi:10.1055/s-2006-944545 · Cited by 67
Radiation Therapy for Cushing's Disease: A Review
Mahmoud-Ahmed, A. S., & Suh, J. H. (2002) · Pituitary · doi:10.1023/a:1023365200437 · Cited by 66
Effects of etomidate on steroid biosynthesis in subcellular fractions of bovine adrenals
BOSSCHE, H. V., Willemsens, G., Cools, W., & Bellens, D. (1984) · Biochemical Pharmacology · doi:10.1016/0006-2952(84)90052-2 · Cited by 66
Assessment of Cure and Recurrence After Pituitary Surgery for Cushing's Disease
Barbetta, L., Dall’Asta, C., Tomei, G., Locatelli, M., Giovanelli, M. A., & Ambrosi, B. (2001) · Acta Neurochirurgica · doi:10.1007/s007010170077 · Cited by 66
Fleseriu, M., Molitch, M. E., Gross, C., SCHTEINGART, D. E., Vaughan, T. B., & Biller, B. M. K. (2013) · Endocrine Practice · doi:10.4158/ep12149.ra · Cited by 66
Effect of desmopressin on ACTH and cortisol secretion in states of ACTH excess
Colombo, P., Passini, E., Re, T., Faglia, G., & Ambrosi, B. (1997) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1997.1330954.x · Cited by 66
Complete remission of Nelson’s syndrome after 1-year treatment with cabergoline
Pivonello, R., Faggiano, A., Salle, F. D., Filippella, M., Lombardi, G., & Colao, A. (1999) · Journal of Endocrinological Investigation · doi:10.1007/bf03343660 · Cited by 66
Self-citationDRUG CONTROL OF CUSHING'S SYNDROME
Child, D. F., Burke, C. W., Burley, D. M., REES, L. H., & Fraser, T. R. (1976) · European Journal of Endocrinology · doi:10.1530/acta.0.0820330 · Cited by 66
Radiation Therapy of Pituitary Tumors
Tran, L. M., Blount, L., Horton, D., Sadeghi, A., & Parker, R. G. (1991) · American Journal of Clinical Oncology · doi:10.1097/00000421-199102000-00005 · Cited by 65
Schopohl, J., Gu, F., Rubens, R., Gaal, L. V., Bertherat, J. Y., Ligueros‐Saylan, M., Trovato, A., Hughes, G., Salgado, L. R., Boscaro, M., et al. (2014) · Pituitary · doi:10.1007/s11102-014-0618-1 · Cited by 65
Self-citationCoagulopathy in Cushing’s Syndrome
Trementino, L., Arnaldi, G., Appolloni, G., Daidone, V., Scaroni, C. M., Casonato, A., & Boscaro, M. (2010) · Neuroendocrinology · doi:10.1159/000314349 · Cited by 65
Dehdashti, A. R., & Gentili, F. (2007) · Neurosurgical FOCUS · doi:10.3171/foc.2007.23.3.11 · Cited by 65
Mauermann, W. J., Sheehan, J. P., Cherñavvsky, D. R., et al. (2007) · Journal of neurosurgery · doi:10.3171/jns.2007.106.6.988 · Cited by 64
Nonhypnotic low-dose etomidate for rapid correction of hypercortisolaemia in cushing's syndrome
Allolio, B., Schulte, H. M., Kaulen, D., Reincke, M., Jaursch-Hancke, C., & Winkelmann, W. (1988) · Journal of Molecular Medicine · doi:10.1007/bf01735795 · Cited by 64
Carballeira, A., Fishman, L. M., & Jacobi, J. D. (1976) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-42-4-687 · Cited by 63
Aminoglutethimide in the Treatment of Cushing's Syndrome
Misbin, R. I., Canary, J. J., & Willard, D. (1976) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1976.tb01504.x · Cited by 63
Arnott, R. D., Pestell, R. G., McKelvie, P. A., Henderson, J. K., McNeill, P. M., & ALFORD, F. P. (1990) · European Journal of Endocrinology · doi:10.1530/acta.0.1230423 · Cited by 63
Wagenmakers, M. A. E. M., Netea-Maier, R. T., van Lindert, E. J., Timmers, H. J. L. M., Grotenhuis, J. A., & Hermus, A. R. M. M. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03334.x · Cited by 63
KETOCONAZOLE THERAPY IN CUSHING'S DISEASE
Angeli, A., & Frairia, R. (1985) · The Lancet · doi:10.1016/s0140-6736(85)91482-5 · Cited by 62
Honegger, J. B., Schmalisch, K., Beuschlein, F., Kaufmann, S., Schnauder, G., Naegele, T., & Psaras, T. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04268.x · Cited by 61
Classic and Recent Etiologies of Cushing??s Syndrome: Diagnosis and Therapy
Beauregard, C., Dickstein, G., & Lacroix, A. (2002) · Treatments in Endocrinology · doi:10.2165/00024677-200201020-00002 · Cited by 61
Management of hyperglycaemia in Cushing's disease: Experts’ proposals on the use of pasireotide
Reznik, Y., Bertherat, J. Y., Borson‐Chazot, F., Brue, T. C., Chanson, P., Cortet‐Rudelli, C., Delemer, B., Tabarin, A., Bisot-Locard, S., & Vergès, B. L. (2012) · Diabetes & Metabolism · doi:10.1016/j.diabet.2012.10.005 · Cited by 60
Treatment of Cushing's disease: a mechanistic update
Ramos, D. C., & Fleseriu, M. (2014) · Journal of Endocrinology · doi:10.1530/joe-14-0300 · Cited by 60
The medical management of Cushing's syndrome during pregnancy
Lim, W. H., Torpy, D. J., & Jeffries, W. S. (2013) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2012.12.015 · Cited by 60
Phenomenology and family history of affective disorder in Cushing's disease
Hudson, J. I., Hudson, M., Griffing, G. T., Melby, J. C., & Pope, H. G. (1987) · American Journal of Psychiatry · doi:10.1176/ajp.144.7.951 · Cited by 60
Schrell, U. M. H., Fahlbusch, R., Buchfelder, M., Riedl, S., Stalla, G. K., & Müller, O. A. (1987) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-64-6-1150 · Cited by 59
Mortality in Cushing’s Disease
Clayton, R. N. (2010) · Neuroendocrinology · doi:10.1159/000315813 · Cited by 58
Mifepristone for Management of C ushing's Syndrome
Morgan, F. H., & Laufgraben, M. J. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1202 · Cited by 58
Hart, M. M., Swackhamer, E. S., & Straw, J. A. (1971) · Steroids · doi:10.1016/s0039-128x(71)80158-7 · Cited by 58
Prospective evaluation of transsphenoidal pituitary surgery in 108 patients with Cushing's disease
Rollin, G., Ferreira, N. P., & Czepielewski, M. A. (2007) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302007000800022 · Cited by 58
Laparoscopic bilateral adrenalectomy for persistent Cushing's disease after transsphenoidal surgery
Lanzi, R., Montorsi, F., Losa, M., et al. (1998) · Surgery · doi:10.1016/s0039-6060(98)70251-x · Cited by 57
Surgical Treatment of Recurrent Cushing's Disease
Hofmann, B., Hlaváč, M., Kreutzer, J., Gg, G., & Fahlbusch, R. (2006) · Neurosurgery · doi:10.1227/01.neu.0000215945.26764.92 · Cited by 56
New mechanisms of adrenostatic compounds in a human adrenocortical cancer cell line
Faßnacht, M., Hahner, S., Beuschlein, F., Klink, A., Reincke, M., & Allolio, B. (2000) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2000.0300s3076.x · Cited by 56
Transsphenoidal surgery for pituitary tumours
Massoud, A. F., Powell, M. P., Williams, R. A., Hindmarsh, P. C., & Brook, C. G. D. (1997) · Archives of Disease in Childhood · doi:10.1136/adc.76.5.398 · Cited by 56
Regulation of ghrelin secretion by somatostatin analogs in rats
Silva, A. P., Bethmann, K., Raulf, F., & SCHMID, H. A. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.01914 · Cited by 56
Growth hormone status following treatment for Cushing's syndrome
Hughes, Lissett, & Shalet, S. M. (1999) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1999.00738.x · Cited by 55
BROMOCRIPTINE IN NELSON'S SYNDROME AND CUSHING'S DISEASE
Lamberts, S. W. J. (1976) · The Lancet · doi:10.1016/s0140-6736(76)90656-5 · Cited by 55
Steroid Biosynthesis Inhibitors in the Therapy of Hypercortisolism: Theory and Practice
Igaz, P., Tömböl, Z., Szabó, P. M., Likó, I., & Rácz, K. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708786242921 · Cited by 55
Jiménez‐Reina, L., Leal‐Cerro, A., García, J. D., García‐Luna, P. P., Astorga, R., & Bernal, G. (1989) · European Journal of Endocrinology · doi:10.1530/acta.0.1210185 · Cited by 55
Flitsch, J., Knappe, U., & Lüdecke, D. (2003) · Zentralblatt für Neurochirurgie · doi:10.1055/s-2003-37145 · Cited by 54
Drug controlled of Cushing's syndrome. Combined aminoglutethimide and metyrapone therapy.
Child, D. F., Burke, C. W., Burley, D. M., REES, L. H., & Fraser, T. R. (1976) · PubMed · Cited by 54
Aminoglutethimide and metyrapone in the management of Cushing's syndrome
Thoren, M., Adamson, U. K. C., & Sjöberg, H. E. (1985) · European Journal of Endocrinology · doi:10.1530/acta.0.1090451 · Cited by 54
Colombo, P., Dall’Asta, C., Barbetta, L., Re, T., Passini, E., Faglia, G., & Ambrosi, B. (2000) · European Journal of Endocrinology · doi:10.1530/eje.0.1430227 · Cited by 54
Ultrastructure of Adrenal Cortex of the Dog During Treatment With DDD 2 , 3
KAMINSKY, N., LUSE, S., & Hartroft, P. M. (1962) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/29.1.127 · Cited by 54
Surgical Experience with Cushingʼs Disease
Scott, H. W., Liddle, G. W., Mulherin, J. L., McKenna, T. J., Stroup, S. L., & Rhamy, R. K. (1977) · Annals of Surgery · doi:10.1097/00000658-197705000-00004 · Cited by 53
Burch, W. M. (1985) · Archives of Internal Medicine · doi:10.1001/archinte.1985.00360060174027 · Cited by 53
Complexing of DDT and o,p'DDD with adrenal cytochrome P-450 hydroxylating systems
Young, R. B., Bryson, M. J., Sweat, M. L., & Street, J. C. (1973) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(73)90033-2 · Cited by 52
Starke, R. M., Williams, B. J., Vance, M. L., & Sheehan, J. P. (2010) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32833ab069 · Cited by 52
Long term follow-up of Cushing's disease treated with reserpine and pituitary irradiation
Murayama, M. A., Yasuda, K., Minamori, Y., MERCADO-ASIS, L. B., Yamakita, N., & Miura, K. (1992) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.75.3.935 · Cited by 52
Katznelson, L. (2013) · Journal of Clinical Endocrinology and Metabolism · doi:10.1210/jc.2013-1497 · Cited by 52
Losa, M., Bianchi, R., Barzaghi, L. R., Giovanelli, M. A., & Mortini, P. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0844 · Cited by 52
Barahona, M. J., Resmini, E., Viladés, D., Pons‐Lladó, G., Leta, R., Puig, T., & Webb, S. M. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3547 · Cited by 52
Radiotherapy for Pituitary Adenomas
Brada, M., & Jankowska, P. (2008) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2007.10.005 · Cited by 51
Simeoli, C., Auriemma, R. S., Tortora, F., Leo, M. D., Iacuaniello, D., Cozzolino, A., Martino, M. C. D., Pivonello, C., Mainolfi, C. G., Rossi, R., et al. (2015) · Endocrine · doi:10.1007/s12020-015-0557-2 · Cited by 51
Self-citationCabergoline Therapy for Cushing Disease Throughout Pregnancy
Woo, I., & Ehsanipoor, R. M. (2013) · Obstetrics and Gynecology · doi:10.1097/aog.0b013e31829e398a · Cited by 51
The use of the glucocorticoid receptor antagonist mifepristone in Cushing's syndrome
Castinetti, F., Brue, T. C., & Conte‐Devolx, B. (2012) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32835430bf · Cited by 51
Survival and causes of death after adrenalectomy for Cushing's disease.
Rb, W. (1985) · PubMed · Cited by 50
ACTH-Producing Pituitary Tumors
Grua, J. R., & Nelson, D. H. (1991) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(18)30271-8 · Cited by 50
Park, S., Kamegai, J., & Kineman, R. D. (2003) · Neuroendocrinology · doi:10.1159/000072798 · Cited by 50
Predicting late recurrence in surgically treated patients with C ushing's disease
Barbot, M., Albiger, N. M. E., Koutroumpi, S., Ceccato, F., Frigo, A. C., Manara, R., Fassina, A., Gardiman, M. P., Scanarini, M., Mantero, F., et al. (2012) · Clinical Endocrinology · doi:10.1111/cen.12133 · Cited by 50
Nelson syndrome: comprehensive review of pathophysiology, diagnosis, and management
Banasiak, M., & Malek, A. R. (2007) · Neurosurgical FOCUS · doi:10.3171/foc-07/09/e13 · Cited by 50
Treatment of Cushing’s Disease: A Retrospective Clinical Study of the Latest 100 Cases
Hofmann, B., & Fahlbusch, R. (2006) · KARGER eBooks · doi:10.1159/000091580 · Cited by 49
Impairment of flow-mediated vasodilatation of brachial artery in patients with Cushing’s Syndrome
Baykan, M., Erem, C., Gedikli, Ö., Hacıhasanoğlu, A., Erdoğan, T., Koçak, M., Durmuş, İ., Korkmaz, L., & Çelik, Ş. (2007) · Endocrine · doi:10.1007/s12020-007-0033-8 · Cited by 49
Global clinical response in C ushing's syndrome patients treated with mifepristone
Katznelson, L. J., Loriaux, D. L., Feldman, D., Braunstein, G. D., SCHTEINGART, D. E., & Gross, C. (2013) · Clinical Endocrinology · doi:10.1111/cen.12332 · Cited by 49
Castinetti, F., Martinie, M., Morange, I., Dufour, H., Stürm, N., Passagia, J., Conte‐Devolx, B., Chabre, O., & Brue, T. C. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2234 · Cited by 49
Recurrent Cushing's Disease After Transsphenoidal Surgery
Tahir, A. H. (1992) · Archives of Internal Medicine · doi:10.1001/archinte.1992.00400170067013 · Cited by 49
Boronat, M., Marrero, D., López-Plasencia, Y., Barber, M. Á., Schamann, Y., & Novoa, F. J. (2010) · Gynecological Endocrinology · doi:10.3109/09513590.2010.521268 · Cited by 49
Valéro, R., Vallette-Kasic, S., Conte-Devolx, B., Jaquet, P., & Brue, T. (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.1510727 · Cited by 49
Management of recurrent and refractory Cushing disease
Aghi, M. K. (2008) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0947 · Cited by 48
Moncet, D., Morando, D. J., Pitoia, F., Katz, S. B., Rossi, M., & Bruno, O. D. (2007) · PubMed · Cited by 48
Treatment options for Cushing disease after unsuccessful transsphenoidal surgery
Liu, J. K., Fleseriu, M., Delashaw, J. B., Ciric, I. S., Couldwell, W. T., & Ph.D., P. D. (2007) · Neurosurgical FOCUS · doi:10.3171/foc.2007.23.3.10 · Cited by 47
Storr, H. L., Drake, W. M., Evanson, J., Matson, M. B., Berney, D. M., Grossman, A. B., Akker, S. A., Monson, J. P., Alusi, G., Savage, M. O., et al. (2013) · Clinical Endocrinology · doi:10.1111/cen.12275 · Cited by 47
ACTH silent adenoma shrinking under cabergoline
Pétrossians, P., Ronci, N., Socin, H. V., Kalife, A., Stevenaert, A., Bloch, B., Tabarin, A., & Beckers, A. M. (2001) · European Journal of Endocrinology · doi:10.1530/eje.0.1440051 · Cited by 47
Tsagarakis, Vasiliou, Kokkoris, Stavropoulos, & Thalassinos (1999) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1999.00830.x · Cited by 46
The trans-sphenoidal resection of pituitary adenomas in elderly patients and surgical risk
Locatelli, M., Bertani, G., Carrabba, G. G., Rampini, P. M., Zavanone, M. L., Caroli, M., Sala, E., Ferrante, E., Gaini, S. M., Spada, A., et al. (2012) · Pituitary · doi:10.1007/s11102-012-0390-z · Cited by 46
DIRECT IN VITRO INHIBITION OF ADRENAL STEROIDOGENESIS BY ETOMIDATE
Lambert, A. W., Mitchell, R. M., Frost, J., Ratcliffe, J. G., & Robertson, W. R. (1983) · The Lancet · doi:10.1016/s0140-6736(83)91070-x · Cited by 46
Grant, R. A., Whicker, M. E., Lleva, R. R., Knisely, J. P. S., Inzucchi, S. E., & Chiang, V. (2013) · World Neurosurgery · doi:10.1016/j.wneu.2013.01.127 · Cited by 46
THE INHIBITION BY ETOMIDATE OF THE 11β‐HYDROXYLATION OF CORTISOL
Fry, D. E., & Griffiths, H. R. (1984) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1984.tb00112.x · Cited by 46
Wilson, P. J., Williams, J. R., & Smee, R. I. (2013) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2013.04.007 · Cited by 45
New developments in the medical treatment of Cushing's syndrome
van der Pas, R., de Herder, W. W., Hofland, L. J., & Feelders, R. A. (2012) · Endocrine Related Cancer · doi:10.1530/erc-12-0191 · Cited by 45
Feigl, G. C., Pistracher, K., Berghold, A., & Mokry, M. (2010) · Journal of neurosurgery · doi:10.3171/2010.8.gks10959 · Cited by 45
Bakiri, F., Tatai, S., Aouali, R., Semrouni, M., Derome, P., Chitour, F., & Benmiloud, M. (1996) · Journal of Endocrinological Investigation · doi:10.1007/bf03349020 · Cited by 44
TREATMENT OF CUSHING'S SYNDROME WITH THE LONG‐ACTING SOMATOSTATIN ANALOGUE SMS 201‐995 (SANDOSTATIN)
Invitti, C., Martin, M., Brunani, A., Piolini, M., & Cavagnini, F. (1990) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1990.tb00867.x · Cited by 44
Laws, E. R. (1987) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(18)30467-5 · Cited by 44
Bilateral adrenalectomy for Cushing’s syndrome: A comparison between laparoscopy and open surgery
Porpiglia, F., Fiori, C., Bovio, S., Destefanis, P., Alı̀, A., Terrone, C., Fontana, D., Scarpa, R. M., Tempia, A., & Terzolo, M. (2004) · Journal of Endocrinological Investigation · doi:10.1007/bf03347498 · Cited by 43
Transsphenoidal surgery in Cushing disease: 10 years of experience in 34 consecutive cases
Höybye, C., Grenbäck, E., Thorén, M. C., Hulting, A., Lundblad, L., von Holst, H., & Änggård, A. (2004) · Journal of neurosurgery · doi:10.3171/jns.2004.100.4.0634 · Cited by 43
Schwartz, E., Mezick, J. A., Gendimenico, G. J., & Kligman, L. H. (1994) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12371770 · Cited by 43
BOSCARO, M., SONINO, N., RAMPAZZO, A., & MANTERO, F. (1987) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1987.tb01174.x · Cited by 43
INHIBITION BY ETOMIDATE OF STEROIDOGENESIS IN ISOLATED BOVINE ADRENAL CELLS
Kenyon, C. J., Young, J., GRAY, C. E., & Fräser, R. (1984) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-58-5-947 · Cited by 43
Ineffectiveness of Rosiglitazone Therapy in Nelson’s Syndrome
Munir, A., Song, F., Ince, P. G., Walters, S. J., Ross, R. J. M., & Newell-Price, J. D. C. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2005 · Cited by 42
Romanholi, D. J. P. C., Machado, M. C., Pereira, C. C., Danilovic, D. L. S., Pereira, M. A. A., Cescato, V. Â. S., Neto, M. B. C. C., Musolino, N. R. D. C., Mendonca, B. B., & Salgado, L. R. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.03168.x · Cited by 42
Graham, K. E., Samuels, M. H., Raff, H., Barnwell, S., & Cook, D. M. (1997) · Journal of Clinical Endocrinology and Metabolism · doi:10.1210/jcem.82.6.4005 · Cited by 42
Faggiano, A., Melis, D., Alfieri, R., Martino, M. C. D., Filippella, M., Milone, F., Lombardi, G., Colao, A., & Pivonello, R. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0656 · Cited by 42
Self-citationEffect of the serotonin antagonists ritanserin and ketanserin in Cushing’s disease
Sonino, N., Fava, G. A., Fallo, F., Franceschetto, A., Belluardo, P., & Boscaro, M. (2000) · Pituitary · doi:10.1023/a:1009986822146 · Cited by 41
Cardiovascular autonomic function in Cushing’s syndrome
Fallo, F., Maffei, P., Pozza, A. D., Carli, M., Mea, P. D., Lupia, M., Rabbia, F., & Sonino, N. (2009) · Journal of Endocrinological Investigation · doi:10.1007/bf03345677 · Cited by 41
Results of repeated transsphenoidal surgery in Cushing's disease. Long-term follow-up
Valderrábano, P., Aller, J., García‐Valdecasas, L., García-Uría, J., Martín, L., Palacios, N., & Estrada, J. S. (2013) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2013.10.008 · Cited by 41
Mullan, K., Leslie, H., McCance, D. R., Sheridan, B., & Atkinson, A. B. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02501.x · Cited by 40
Epidemiology and follow-up of Cushing's disease.
Cavagnini, F., & Giraldi, F. P. (2001) · PubMed · Cited by 40
Feigl, G. C., Pistracher, K., Berghold, A., & Mokry, M. (2010) · PubMed · Cited by 39
Management of Diabetes Mellitus in Cushing’s Syndrome
Munir, A., & Newell-Price, J. D. C. (2010) · Neuroendocrinology · doi:10.1159/000314316 · Cited by 39
Medical Treatment of Cushing’s Disease: Somatostatin Analogues and Pasireotide
Pedroncelli, A. M. (2010) · Neuroendocrinology · doi:10.1159/000314352 · Cited by 39
Transsphenoidal surgery for Cushing's disease: defining cure and following outcome *
Newell-Price, J. (2002) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2002.01369.x · Cited by 39
Mehta, G. U., Sheehan, J. P., & Vance, M. L. (2013) · Journal of neurosurgery · doi:10.3171/2013.7.jns13389 · Cited by 38
Milian, M., Teufel, P., Honegger, J. B., Gallwitz, B., Schnauder, G., & Psaras, T. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04191.x · Cited by 38
The pituitary before and after adrenalectomy for Cushing's syndrome
Manolas, K. J., Farmer, H. M., Wilson, H. K., et al. (1984) · World Journal of Surgery · doi:10.1007/bf01655082 · Cited by 38
MacKenzie Feder, J., Bourdeau, I., Vallette, S., Beauregard, H., Ste-Marie, L.-G., & Lacroix, A. (2014) · Pituitary · doi:10.1007/s11102-013-0539-4 · Cited by 38
Ménard, J., Watson, C. E., Rebello, S. S., Zhang, Y. M., & Dole, W. P. (2010) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(10)60584-0 · Cited by 38
Cortisol, 11β-Hydroxysteroid Dehydrogenases, and Hypertension
Uum, S. H. M. V., Lenders, J. W. M., & Hermus, A. R. (2004) · Seminars in Vascular Medicine · doi:10.1055/s-2004-835369 · Cited by 38
Early promising results for the endoscopic surgical treatment of Cushing’s disease
Berker, M., Işıkay, İ., Berker, D. S., Bayraktar, M., & Gürlek, A. (2013) · Neurosurgical Review · doi:10.1007/s10143-013-0506-6 · Cited by 38
Update in the medical therapy of Cushing's disease
Nieman, L. K. (2013) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3283631809 · Cited by 38
Czirják, S., Bezzegh, A., Gál, A., & Rácz, K. (2002) · Acta Neurochirurgica · doi:10.1007/s00701-002-0984-8 · Cited by 37
Circadian Blood Pressure Profile in Patients with Active Cushing's Disease and after Long-term Cure
Giraldi, F. P., Toja, P. M., Martin, M., Maronati, A., Scacchi, M., Omboni, S., Cavagnini, F., & Parati, G. (2007) · Hormone and Metabolic Research · doi:10.1055/s-2007-992813 · Cited by 37
Update on radiation therapy in patients with Cushing’s disease
Tritos, N. A., & Biller, B. M. K. (2014) · Pituitary · doi:10.1007/s11102-014-0615-4 · Cited by 37
Milian, M., Teufel, P., Honegger, J. B., Gallwitz, B., Schnauder, G., & Psaras, T. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04280.x · Cited by 37
Chan, L. F., Vaidya, M., Westphal, B., Allgrove, J., Martin, L., Afshar, F., Hindmarsh, P. C., Savage, M. O., Grossman, A. B., & Storr, H. L. (2011) · Hormone Research in Paediatrics · doi:10.1159/000324419 · Cited by 37
Criteria of cure and remission in Cushing's disease: an update
Czepielewski, M. A., Rollin, G., Casagrande, A., & Ferreira, N. P. D. F. (2007) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302007000800023 · Cited by 37
Henry, R. R., Mudaliar, S. R. D., Wetli-Hermosillo, K., Ligueros‐Saylan, M., Chenji, S., & Golor, G. (2011) · The Endocrine Society eBooks · doi:10.1210/endo-meetings.2011.part3.p30.p3-274 · Cited by 36
Human Cytochrome P450: Metabolism of Testosterone by CYP3A4 and Inhibition by Ketoconazole
Usmani, K. A., & Tang, J. (2004) · Current Protocols in Toxicology · doi:10.1002/0471140856.tx0413s20 · Cited by 36
van den Bosch, O. F. C., Stades, A. M. E., & ZELISSEN, P. M. J. (2013) · Clinical Endocrinology · doi:10.1111/cen.12286 · Cited by 36
Cavagnini, F., Panerai, A. E., VALENTINI, F., Bulgheroni, P., PERACCHI, M., & PINTO, M. (1975) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-41-1-143 · Cited by 36
Somatostatin Analogues: Treatment of Pituitary and Neuroendocrine Tumors
Colao, A., Faggiano, A., & Pivonello, R. (2010) · Progress in brain research · doi:10.1016/s0079-6123(10)82012-6 · Cited by 35
Self-citationImpact of Technique on Cushing Disease Outcome Using Strict Remission Criteria
Alahmadi, H., Cusimano, M. D., Woo, K., Mohammed, A. A., Goguen, J., Smyth, H. S., Macdonald, R. L., Müller, P. J., Horváth, É., & Kovács, K. (2013) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s031716710001427x · Cited by 35
Failure of long-term therapy with sodium valproate in Cushing’s disease
Colao, A., Pivonello, R., Tripodi, F., Orio, F., Ferone, D., Cerbone, G., Somma, C. D., Merola, B., & Lombardi, G. (1997) · Journal of Endocrinological Investigation · doi:10.1007/bf03347989 · Cited by 35
Self-citationHistological changes in the pituitary gland and adenomas following radiotherapy
Nishioka, H., Hirano, A., Haraoka, J., et al. (2002) · Neuropathology · doi:10.1046/j.0919-6544.2001.00426.x · Cited by 35
Shimon, I., Rot, L., & Inbar, E. (2012) · Pituitary · doi:10.1007/s11102-012-0427-3 · Cited by 35
Bilateral Laparoscopic Adrenalectomy for Adrenocorticotropic Dependent Cushing's Syndrome
Ferrer, F. A., MacGillivray, D. C., Malchoff, C. D., et al. (1997) · The Journal of Urology · doi:10.1016/s0022-5347(01)65269-8 · Cited by 35
Medical Treatment in Cushing’s Syndrome: Dopamine Agonists and Cabergoline
Pétrossians, P., Thonnard, A.-S., & Beckers, A. M. (2010) · Neuroendocrinology · doi:10.1159/000317716 · Cited by 34
Shah, N. S., George, J., Acharya, S. V., Lila, A. R., Sarathi, V., Bandgar, T., Jalali, R., Goel, A. H., & Menon, P. S. N. (2010) · Endocrine Practice · doi:10.4158/ep10143.or · Cited by 34
Medical management of Cushing disease
Gross, B. A., Mindea, S. A., Pick, A. J., Chandler, J. P., & Batjer, H. H. (2007) · Neurosurgical FOCUS · doi:10.3171/foc.2007.23.3.12 · Cited by 34
Medical Management of Persistent and Recurrent Cushing Disease
Fleseriu, M. (2012) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2012.06.012 · Cited by 34
Cushing’s disease: Results of treatment and factors affecting outcome
Ammini, A. C., Bhattacharya, S., Sahoo, J. P., Philip, J., Tandon, N., Goswami, R., Jyotsna, V. P., Khadgawat, R., Chumber, S., Seth, A., et al. (2011) · HORMONES · doi:10.14310/horm.2002.1312 · Cited by 34
Hypopituitarism and Central Diabetes Insipidus
Devin, J. K. (2012) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2012.06.001 · Cited by 33
Management of recurrent Cushing’s disease
Liubinas, S. V., del Porto, L. A., & Kaye, A. H. (2010) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2010.05.001 · Cited by 33
Long-Term Effects of Ketoconazole in the Treatment of Residual or Recurrent Cushing's Disease.
CHOU, S.-C., & Lin, J. (2000) · Endocrine Journal · doi:10.1507/endocrj.47.401 · Cited by 33
PITUITARY FUNCTION FOLLOWING MEGAVOLTAGE THERAPY FOR CUSHING'S DISEASE: LONG TERM FOLLOW UP
SHARPE, G. F., Kendall-Taylor, P., Prescott, R. W. G., ROSS, W. M., Davison, C. B., Watson, M. J., & Cook, D. B. (1985) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1985.tb01078.x · Cited by 33
Mifepristone: is there a place in the treatment of Cushing’s disease?
Carmichael, J. D., & Fleseriu, M. (2012) · Endocrine · doi:10.1007/s12020-012-9846-1 · Cited by 33
Treatment of Cushing's disease with adrenal blocking drugs and megavoltage therapy to the pituitary
Ross, W. M., Evered, D. C., Hunter, P., Benaim, M. E., Cook, D., & Hall, R. (1979) · Clinical Radiology · doi:10.1016/s0009-9260(79)80135-x · Cited by 33
Feelders, R. A., Yasothan, U., & Kirkpatrick, P. N. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3788 · Cited by 33
Utility of the Immediate Postoperative Cortisol Concentrations in Patients With Cushing's Disease
Sughrue, M. E., Shah, J. K., Devin, J. K., Kunwar, S., & Blevins, L. S. (2010) · Neurosurgery · doi:10.1227/01.neu.0000374722.50042.ff · Cited by 32
Peri-operative management of Cushing’s disease
Abdelmannan, D. K., Selman, W. R., & Arafah, B. M. (2010) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-010-9140-6 · Cited by 32
Twin pregnancy in a patient with Cushing’s disease
Cabezón, C., Bruno, O. D., Cohen, M. G., García, S. A. L., & Gutman, R. A. (1999) · Fertility and Sterility · doi:10.1016/s0015-0282(99)00261-7 · Cited by 32
Shraga-Slutzky, I., Shimon, I., & Weinshtein, R. (2006) · Pituitary · doi:10.1007/s11102-006-9290-4 · Cited by 31
Trementino, L., Cardinaletti, M., Concettoni, C., Marcelli, G., Boscaro, M., & Arnaldi, G. (2014) · Pituitary · doi:10.1007/s11102-014-0582-9 · Cited by 31
Management of Dyslipidemia in Cushing’s Syndrome
Greenman, Y. (2010) · Neuroendocrinology · doi:10.1159/000314294 · Cited by 31
Srinivasan, L., Laws, E. R., Dodd, R. L., Monita, M. M., Tannenbaum, C. E., Kirkeby, K. M., Chu, O. S., Harsh, G. R., & Katznelson, L. J. (2011) · Pituitary · doi:10.1007/s11102-011-0295-2 · Cited by 31
Radiotherapy and radiosurgery for Cushing's disease
Minniti, G. C., & Brada, M. (2007) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302007000800024 · Cited by 31
Medical management of Cushing’s disease
Tritos, N. A., & Biller, B. M. K. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1269-1 · Cited by 30
CROUGHS, R. J. M., Koppeschaar, H. P. F., Verlaat, J. W. V. '., & McNICOL, A. M. (1989) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-68-2-495 · Cited by 30
Krikorian, A., Abdelmannan, D. K., Selman, W. R., & Arafah, B. M. (2007) · Neurosurgical FOCUS · doi:10.3171/foc.2007.23.3.8 · Cited by 30
Miyoshi, T., Otsuka, F., Takeda, M., Inagaki, K., Suzuki, J., Ogura, T., Date, I., Hashimoto, K., & Makino, H. (2004) · Journal of Endocrinological Investigation · doi:10.1007/bf03345309 · Cited by 29
Ayala, A. R., & Manzano, A. J. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1508-0 · Cited by 29
Benecke, R., Keller, E., Vetter, B., & de Zeeuw, R. A. (1991) · European Journal of Clinical Pharmacology · doi:10.1007/bf00315440 · Cited by 29
Nagesser, S. K., van Seters, A. P., Kievit, J., Hermans, J., Dulken, H. V., Krans, H. M. J., & van de Velde, C. J. H. (2000) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2000.00958.x · Cited by 29
The therapy of Cushing’s disease in adults and children: an update
Juszczak, A., Ertorer, M., & Grossman, A. (2012) · Hormone and Metabolic Research · doi:10.1055/s-0032-1330009 · Cited by 28
Transient inhibition of RU 486 Antiglucocorticoid Action by Dexamethasone
Raux-Demay, M. C., Pierret, T., d'Yvoire, M. B., BERTAGNA, X. Y., & Girard, F. (1990) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-70-1-230 · Cited by 28
Gamma Knife Radiosurgery as a Primary Surgical Treatment for Hypersecreting Pituitary Adenomas
Zhang, N., Pan, L., Dai, J., Wang, B., Wang, E., Zhang, W., & Cai, P.-W. (2000) · Stereotactic and Functional Neurosurgery · doi:10.1159/000048393 · Cited by 28
ZACHMANN, M., GITZELMANN, R., Zagalak, M.-J., & Prader, A. (1977) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1977.tb02940.x · Cited by 28
Stereotactic radiosurgery for Cushing disease: a review
Oyesiku, N. M. (2007) · Neurosurgical FOCUS · doi:10.3171/foc-07/12/e14 · Cited by 28
Diagnosis, management and therapeutic outcome in prepubertal Cushing's disease
Dias, R. P., Kumaran, A., Chan, L. F., Martin, L., Afshar, F., Matson, M. B., Plowman, P. N., Monson, J., BESSER, G. M., Grossman, A. B., et al. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0509 · Cited by 28
Long-term Results of Radiation Therapy for Pituitary Adenoma
Kokubo, M., Sasai, K., Shibamoto, Y., Aoki, T., Oya, N., Mitsumori, M., Takahashi, J. A., Hashimoto, N., & Hiraoka, M. (2000) · Journal of Neuro-Oncology · doi:10.1023/a:1006450024305 · Cited by 27
Successful control of Cushing's disease in the elderly with long term metyrapone
Donckier, J. E., Burrin, J. M., Ramsay, I. D., & Joplin, G. F. (1986) · Postgraduate Medical Journal · doi:10.1136/pgmj.62.730.727 · Cited by 27
What Can Predict Postoperative “Endocrinological Cure” in Cushing's Disease?
Nishizawa, S., Oki, Y., Ohta, S., Yokota, N., Yokoyama, T., & Uemura, K. (1999) · Neurosurgery · doi:10.1097/00006123-199908000-00007 · Cited by 27
Different therapeutic efficacy of ketoconazole in patients with Cushing's syndrome
Engelhardt, D., Jacob, K., & Doerr, H. G. (1989) · Journal of Molecular Medicine · doi:10.1007/bf01717326 · Cited by 27
THE PITUITARY‐ADRENAL RESPONSE TO CRF‐41 IS UNALTERED BY INTRAVENOUS SOMATOSTATIN IN NORMAL SUBJECTS
Stafford, P. J., Kopelman, P. G., DAVIDSON, K., McLoughlin, L., White, A. E., REES, L. H., BESSER, G. M., Coy, D. H., & Grossman, A. B. (1989) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1989.tb00272.x · Cited by 26
Cushing’s disease: radiation therapy
Vance, M. L. (2008) · Pituitary · doi:10.1007/s11102-008-0117-3 · Cited by 26
Long-Term Treatment of Central Cushing's Syndrome with Rosiglitazone
Morcos, M., Fohr, B., Tafel, J., Pfisterer, F., Hamann, A., Humpert, P. M., Bode, H., Schwenger, V., Zeier, M., Becker, C., et al. (2007) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-2007-970162 · Cited by 26
The effects of octreotide in a patient with Nelson’s syndrome
Keleştimur, F., Utaş, C., Özbakır, Ö., Selcuklu, A., Kandemir, O., & Özcan, N. (1996) · Postgraduate Medical Journal · doi:10.1136/pgmj.72.843.53 · Cited by 26
Fatal Liver Failure due to Ketoconazole Treatment of a Girl with Cushing's Syndrome
Zöllner, E. W., DELPORT, S., & Bonńici, F. (2001) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem.2001.14.3.335 · Cited by 26
Dall’Asta, C., Barbetta, L., Bonavina, L., Beck‐Peccoz, P., & Ambrosi, B. (2004) · Pituitary · doi:10.1007/s11102-005-0425-9 · Cited by 26
Wallia, A., Colleran, K., Purnell, J. Q., Gross, C., & Molitch, M. E. (2013) · Diabetes Care · doi:10.2337/dc13-0246 · Cited by 25
An approach to the management of patients with residual Cushing’s disease
Blevins, L. S., Sanai, N., Kunwar, S., & Devin, J. K. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9888-2 · Cited by 25
Liu, J. K., Schmidt, M. H., MacDonald, J. D., Jensen, R. L., & Couldwell, W. T. (2003) · Neurosurgical FOCUS · doi:10.3171/foc.2003.14.5.12 · Cited by 24
Macroprolactinoma associated with Cushing’s disease, successfully treated with cabergoline
T'Sjoen, G. G., Defeyter, I. R., den Saffele, J. K. V., Rubens, R., & Vandeweghe, M. (2002) · Journal of Endocrinological Investigation · doi:10.1007/bf03343983 · Cited by 24
Cannavò, S., Ambrosi, B., Chiodini, I., Vigo, T., Russo, A., Milici, C., Barbetta, L., Dall’Asta, C., Adda, G., & Arosio, M. (2004) · Journal of Endocrinological Investigation · doi:10.1007/bf03345281 · Cited by 24
Hull, S. S. A., Sheridan, B., & Atkinson, A. B. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02193.x · Cited by 24
de Oliveira, R. S., de Castro, M., Antonini, S. R. R., Martinelli, C. E., Moreira, A. C., & Machado, H. R. (2010) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302010000100004 · Cited by 23
Effect of injectable bromocriptine in patients with Cushing's disease
Invitti, C., Martin, M., Danesi, L., & Cavagnini, F. (2009) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0029-1211361 · Cited by 23
Pasireotide for the treatment of Cushing's disease
Arnaldi, G., & Boscaro, M. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.495943 · Cited by 23
Successful Long-Term Treatment of Cushing Disease with Mifepristone (RU486)
Basina, M., Liu, H., Hoffman, A. R., & Feldman, D. (2012) · Endocrine Practice · doi:10.4158/ep11391.cr · Cited by 23
KETOCONAZOLE AND PLASMA AND URINE STEROID LEVELS IN CUSHING'S DISEASE
Mortimer, R. H., Cannell, G. R., Thew, C. M., & Galligan, J. (1991) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.1991.tb01492.x · Cited by 23
Stone, J., Furuya‐Kanamori, L., Barendregt, J. J., & Doi, S. A. R. (2014) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3736 · Cited by 22
Kim, J. H., Shin, C. S., Paek, S. H., Jung, H., Kim, S. W., & Kim, S.-Y. (2012) · Endocrine Journal · doi:10.1507/endocrj.ej12-0109 · Cited by 22
Stereotactic radiosurgery for treatment of C ushing disease: an A ustralian experience
Wein, L., Dally, M. J., & Bach, L. A. (2012) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2012.02903.x · Cited by 22
Budyal, S. R., Lila, A. R., Jalali, R., Gupta, T., Kasliwal, R., Jagtap, V. S., Bandgar, T., Menon, P. S. N., & Shah, N. S. (2013) · Pituitary · doi:10.1007/s11102-013-0466-4 · Cited by 22
Dopamine D2 receptor expression in the corticotroph cells of the human normal pituitary gland
Pivonello, R., Waaijers, M., Kros, J. M., Pivonello, C., de Angelis, C., Cozzolino, A., Colao, A. A. L., Lamberts, S. W. J., & Hofland, L. J. (2016) · Endocrine · doi:10.1007/s12020-016-1107-2 · Cited by 22
Self-citationRole of the PPAR-γ System in Normal and Tumoral Pituitary Corticotropic Cells and Adrenal Cells
Mannelli, M., Cantini, G., Poli, G., et al. (2010) · Neuroendocrinology · doi:10.1159/000314312 · Cited by 21
Terzolo, M., Panarelli, M., Piovesan, A., TORTA, M., Paccotti, P., & Angeli, A. (1988) · Journal of Endocrinological Investigation · doi:10.1007/bf03350926 · Cited by 21
Guthrie, F. W., Ciric, I. S., Hayashida, S., Kerr, W. D., & Murphy, E. D. (1981) · Surgical Neurology · doi:10.1016/0090-3019(81)90262-7 · Cited by 21
Thyroid function in children with Cushing's disease before and after transsphenoidal surgery
Stratakis, C. A., Mastorakas, G., Magiakou, M.-A., Papavasiliou, E., Oldfield, E. H., & Chrousos, G. P. (1997) · The Journal of Pediatrics · doi:10.1016/s0022-3476(97)70041-6 · Cited by 21
Etomidate in the emergency management of hypercortisolemia
Soh, L. M., Gunganah, K., Akker, S. A., Jones, P., Khachi, H., Dodzo, K., & Drake, W. M. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0698 · Cited by 21
Primary Therapy for Cushing's Disease With Metyrapone
Dickstein, G., Lahav, M., Shen-Orr, Z., Edoute, Y., & Barzilai, D. (1986) · JAMA · doi:10.1001/jama.1986.03370090089027 · Cited by 20
RU 486 ADMINISTRATION IN A CHILD WITH CUSHING'S SYNDROME
Beaufrère, B., de Parscau, L., Chatelain, P., Morel, Y., Aguercif, M., & François, R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)90796-3 · Cited by 20
Heaney, A. P. (2004) · Pituitary · doi:10.1007/s11102-005-1430-8 · Cited by 20
van der Pas, R., van Esch, J. H. M., de Bruin, C., Danser, A. H. J., Pereira, A. M., ZELISSEN, P. M. J., Netea-Maier, R. T., Sprij-Mooij, D. M., Garrelds, I. M., van Schaik, R. H. N., et al. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0477 · Cited by 20
Research works printed but not linked: 143
- Lüdecke, 1976, Selective removal of hypersecreting pituitary adenomas? An analysis of endocrine function, operative and microscopical findings in 101 cases, Acta Neurochir (Wien), 35, 27, 10.1007/BF01405930 · doi:10.1007/bf01405930
- Carmalt, 1977, The treatment of Cushing's disease by trans-sphenoidal hypophysectomy, Q J Med, 46, 119
- Wajchenberg, 1979, Evaluation of resection of pituitary microadenoma for the treatment of Cushing's disease in patients with radiologically normal sella turcica, Clin Endocrinol (Oxf), 11, 323, 10.1111/j.1365-2265.1979.tb03081.x · doi:10.1111/j.1365-2265.1979.tb03081.x
- Hardy, 1982, Presidential address: XVII Canadian Congress of Neurological Sciences. Cushing's disease: 50 years later, Can J Neurol Sci, 9, 375, 10.1017/S0317167100044279 · doi:10.1017/s0317167100044279
- Thomas, 1983, Long term results of radical hypophysectomy for Cushing's disease, Clin Endocrinol (Oxf), 19, 629, 10.1111/j.1365-2265.1983.tb00041.x · doi:10.1111/j.1365-2265.1983.tb00041.x
- Brand, 1985, Long-term follow up of trans-sphenoidal hypophysectomy for Cushing's disease, J R Soc Med, 78, 291, 10.1177/014107688507800404 · doi:10.1177/014107688507800404
- Tagliaferri, 1986, Transsphenoidal microsurgery for Cushing's disease, Acta Endocrinol (Copenh), 113, 5, 10.1530/acta.0.1130005 · doi:10.1530/acta.0.1130005
- van Aken, 1997, Postoperative metyrapone test in the early assessment of outcome of pituitary surgery for Cushing's disease, Clin Endocrinol (Oxf), 47, 145, 10.1046/j.1365-2265.1997.2541051.x · doi:10.1046/j.1365-2265.1997.2541051.x
- Vignati, 1994, Early postoperative evaluation in patients with Cushing's disease: usefulness of ovine corticotropin-releasing hormone test in the prediction of recurrence of disease, Eur J Endocrinol, 130, 235, 10.1530/eje.0.1300235 · doi:10.1530/eje.0.1300235
- Powell, 2009, Microscope and endoscopic pituitary surgery, Acta Neurochirurgica, 151, 723, 10.1007/s00701-009-0297-2 · doi:10.1007/s00701-009-0297-2
- Ciric, 2002, Transsphenoidal microsurgery, Neurosurgery, 51, 161, 10.1097/00006123-200207000-00023 · doi:10.1097/00006123-200207000-00023
- Ciric, 2006, Transsphenoidal microsurgery: past, present and future, Expert Rev Anticancer Ther, 6, S75, 10.1586/14737140.6.9s.S75 · doi:10.1586/14737140.6.9s.s75
- Cappabianca, 1998, Endoscopic endonasal transsphenoidal approach to the sella: towards functional endoscopic pituitary surgery (FEPS), Minim Invasive Neurosurg, 41, 66, 10.1055/s-2008-1052019 · doi:10.1055/s-2008-1052019
- Cappabianca, 2004, Endoscopic endonasal transsphenoidal surgery, Neurosurgery, 55, 933, 10.1227/01.NEU.0000137330.02549.0D · doi:10.1227/01.neu.0000137330.02549.0d
- Strychowsky, 2011, Purely endoscopic transsphenoidal surgery versus traditional microsurgery for resection of pituitary adenomas: systematic review, J Otolaryngol Head Neck Surg, 40, 175
- Laws, 2014, The transition from microscopic to endoscopic transsphenoidal surgery: the experience at Brigham and Women's Hospital, World Neurosurg, 82, S152, 10.1016/j.wneu.2014.07.035 · doi:10.1016/j.wneu.2014.07.035
- Haddad, 1991, Pediatric pituitary tumors, Neurosurgery, 29, 509, 10.1227/00006123-199110000-00004 · doi:10.1227/00006123-199110000-00004
- Mehrazin, 2007, Pituitary tumors in children: clinical analysis of 21 cases, Childs Nerv Syst, 23, 391, 10.1007/s00381-006-0259-4 · doi:10.1007/s00381-006-0259-4
- Doniach, 1977, Histopathology of the anterior pituitary, Clin Endocrinol Metab, 6, 21, 10.1016/S0300-595X(77)80055-8 · doi:10.1016/s0300-595x(77)80055-8
- Kovács, 2013, ACTH-secreting Crooke cell carcinoma of the pituitary, Eur J Clin Invest, 43, 20, 10.1111/eci.12010 · doi:10.1111/eci.12010
- Felix, 1981, Massive Crooke's hyalinization in corticotroph cell adenomas of the human pituitary. A histological, immunocytological, and electron microscopic study of three cases, Acta Neurochir (Wien), 58, 235, 10.1007/BF01407130 · doi:10.1007/bf01407130
- Jho, 1996, Endoscopy assisted transsphenoidal surgery for pituitary adenoma. Technical note, Acta Neurochir (Wien), 138, 1416, 10.1007/BF01411120 · doi:10.1007/bf01411120
- Cappabianca, 2002, Surgical complications associated with the endoscopic endonasal transsphenoidal approach for pituitary adenomas, J Neurosurg, 97, 293, 10.3171/jns.2002.97.2.0293 · doi:10.3171/jns.2002.97.2.0293
- Zada, 2010, Intraoperative conversion from endoscopic to microscopic approach for the management of sellar pathology: incidence and rationale in a contemporary series, World Neurosurg, 73, 334, 10.1016/j.wneu.2010.02.069 · doi:10.1016/j.wneu.2010.02.069
- Murty, 1990, Early inappropriate secretion of antidiuretic hormone after trans-sphenoidal pituitary adenomectomy, J Laryngol Otol, 104, 894, 10.1017/S0022215100114288 · doi:10.1017/s0022215100114288
- Ultmann, 1992, Transient hyponatremia after damage to the neurohypophyseal tracts, Neuroendocrinology, 56, 803, 10.1159/000126310 · doi:10.1159/000126310
- Levy, 1991, Heavy-charged-particle radiosurgery of the pituitary gland: clinical results of 840 patients, Stereotact Funct Neurosurg, 57, 22, 10.1159/000099553 · doi:10.1159/000099553
- Edmonds, 1972, External irradiation of the hypophysis for Cushing's disease, Can Med Assoc J, 107, 860
- Ahmed, 1984, Treatment of Cushing's disease with low dose radiation therapy, Br Med J Clin Res Ed, 289, 643, 10.1136/bmj.289.6446.643 · doi:10.1136/bmj.289.6446.643
- Vicente, 1991, Results of external pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease, Acta Endocrinol (Copenh), 125, 470, 10.1530/acta.0.1250470 · doi:10.1530/acta.0.1250470
- Grigsby, 1988, Long-term results of radiotherapy in the treatment of pituitary adenomas in children and adolescents, Am J Clin Oncol, 11, 607, 10.1097/00000421-198812000-00001 · doi:10.1097/00000421-198812000-00001
- Degerblad, 1986, Long-term results of stereotactic radiosurgery to the pituitary gland in Cushing's disease, Acta Endocrinol (Copenh), 112, 310, 10.1530/acta.0.1120310 · doi:10.1530/acta.0.1120310
- Ganz, 1993, The effects of Gamma Knife surgery of pituitary adenomas on tumor growth and endocrinopathies. Stereotact, Funct Neurosurg, 61, 30, 10.1159/000100657 · doi:10.1159/000100657
- Inoue, 1999, Pituitary adenomas treated by microsurgery with or without Gamma Knife surgery: experience in 122 cases, Stereotact Funct Neurosurg, 72, 125, 10.1159/000056448 · doi:10.1159/000056448
- Mokry, 1999, A six year experience with the postoperative radiosurgical management of pituitary adenomas, Stereotact Funct Neurosurg, 72, 88, 10.1159/000056444 · doi:10.1159/000056444
- Shin, 2000, Stereotactic radiosurgery for pituitary adenoma invading the cavernous sinus, J Neurosurg, 93, 2, 10.3171/jns.2000.93.supplement_3.0002 · doi:10.3171/jns.2000.93.supplement_3.0002
- Kobayashi, 2002, Gamma knife radiosurgery in the treatment of Cushing disease: long-term results, J Neurosurg, 97, 422, 10.3171/jns.2002.97.supplement_5.0422 · doi:10.3171/jns.2002.97.supplement_5.0422
- Wong, 2003, LINAC radiosurgery in recurrent Cushing's disease after transsphenoidal surgery: a series of 5 cases, Minim Invasive Neurosurg, 46, 327, 10.1055/s-2003-812497 · doi:10.1055/s-2003-812497
- Choi, 2003, Radiological and hormonal responses of functioning pituitary adenomas after gamma knife radiosurgery, Yonsei Med J, 44, 602, 10.3349/ymj.2003.44.4.602 · doi:10.3349/ymj.2003.44.4.602
- Kajiwara, 2005, Image-guided stereotactic radiosurgery with the CyberKnife for pituitary adenomas, Minim Invasive Neurosurg, 48, 91, 10.1055/s-2004-830261 · doi:10.1055/s-2004-830261
- Zeiler, 2013, Gamma knife in the treatment of pituitary adenomas: results of a single center, Can J Neurol Sci, 40, 546, 10.1017/S0317167100014645 · doi:10.1017/s0317167100014645
- Kim, 1999, Gamma Knife radiosurgery for functioning pituitary microadenoma, Stereotact Funct Neurosurg, 72, 119, 10.1159/000056447 · doi:10.1159/000056447
- Landolt, 2000, Gamma knife radiosurgery for prolactinomas, J Neurosurg, 93, 14, 10.3171/jns.2000.93.supplement_3.0014 · doi:10.3171/jns.2000.93.supplement_3.0014
- Aristizabal, 1977, Relationship of time dose factors to tumor control and complications in the treatment of Cushing's disease by irradiation, Int J Radiat Oncol Biol Phys, 2, 47, 10.1016/0360-3016(77)90007-4 · doi:10.1016/0360-3016(77)90007-4
- Chen, 2001, Radiosurgical management of benign cavernous sinus tumors: dose profiles and acute complications, Neurosurgery, 48, 1022
- Ove, 2000, Preservation of visual fields after peri-sellar gamma-knife radiosurgery, Int J Cancer, 90, 343, 10.1002/1097-0215(20001220)90:6<343::AID-IJC6>3.0.CO;2-H · doi:10.1002/1097-0215(20001220)90:6<343::aid-ijc6>3.0.co;2-h
- Mehta, 1993, Cavernous sinus cranial neuropathies: is there a dose-response relationship following radiosurgery?, Int J Radiat Oncol Biol Phys, 27, 477, 10.1016/0360-3016(93)90262-T · doi:10.1016/0360-3016(93)90262-t
- Liu, 2005, Gamma knife radiosurgery for tumors involving the cavernous sinus, Stereotact Funct Neurosurg, 83, 45, 10.1159/000085544 · doi:10.1159/000085544
- Kuo, 2004, Gamma knife radiosurgery for benign cavernous sinus tumors: quantitative analysis of treatment outcomes, Neurosurgery, 54, 1385, 10.1227/01.NEU.0000124750.13721.94 · doi:10.1227/01.neu.0000124750.13721.94
- Lundström, 1976, Atrophy of optic nerve fibres in compression of the chiasm. Degree and distribution of ophthalmoscopic changes, Acta Ophthalmol (Copenh), 54, 623, 10.1111/j.1755-3768.1976.tb01291.x · doi:10.1111/j.1755-3768.1976.tb01291.x
- Abe, 2002, Early palliation of oculomotor nerve palsy following gamma knife radiosurgery for pituitary adenoma, Eur Neurol, 47, 61, 10.1159/000047951 · doi:10.1159/000047951
- Packer, 2002, Radiation-induced neurocognitive decline: the risks and benefits of reducing the amount of whole-brain irradiation, Curr Neurol Neurosci Rep, 2, 131, 10.1007/s11910-002-0021-6 · doi:10.1007/s11910-002-0021-6
- Guinan, 1998, Cognitive effects of pituitary tumours and their treatments: two case studies and an investigation of 90 patients, J Neurol Neurosurg Psychiatry, 65, 870, 10.1136/jnnp.65.6.870 · doi:10.1136/jnnp.65.6.870
- Niranjan, 2009, Neoplastic transformation after radiosurgery or radiotherapy: risk and realities, Otolaryngol Clin North Am, 42, 717, 10.1016/j.otc.2009.04.005 · doi:10.1016/j.otc.2009.04.005
- Jones, 1991, Radiation oncogenesis in relation to the treatment of pituitary tumours, Clin Endocrinol (Oxf), 35, 379, 10.1111/j.1365-2265.1991.tb03554.x · doi:10.1111/j.1365-2265.1991.tb03554.x
- Wu-Chen, 2009, Intracranial malignancies occurring more than 20 years after radiation therapy for pituitary adenoma, J Neuroophthalmol, 29, 289, 10.1097/WNO.0b013e3181b4a1be · doi:10.1097/wno.0b013e3181b4a1be
- Ecemis, 2013, Radiation-associated secondary brain tumors after conventional radiotherapy and radiosurgery, Expert Rev Neurother, 13, 557, 10.1586/ern.13.37 · doi:10.1586/ern.13.37
- Tsukamoto, 1992, Meningioma developed 25 years after radiation therapy for Cushing's disease, Intern Med, 31, 629, 10.2169/internalmedicine.31.629 · doi:10.2169/internalmedicine.31.629
- Sarkar, 2014, Radiation-induced opticochiasmatic glioblastoma multiforme following conventional radiotherapy for Cushing's disease, Br J Neurosurg, 28, 510, 10.3109/02688697.2013.841850 · doi:10.3109/02688697.2013.841850
- Larson, 1993, The radiobiology of radiosurgery, Int J Radiat Oncol Biol Phys, 25, 557, 10.1016/0360-3016(93)90080-F · doi:10.1016/0360-3016(93)90080-f
- Croughs, 1971, Immediate effect of unilateral adrenalectomy followed by external pituitary irradiation on cortisol secretion rate in subjects suffering from pituitary dependent Cushing's syndrome, J Clin Endocrinol Metab, 33, 912, 10.1210/jcem-33-6-912 · doi:10.1210/jcem-33-6-912
- Lamberts, 1977, Evaluation of a therapeutic regimen in Cushing's disease. The predictability of the result of unilateral adrenalectomy followed by external pituitary irradiation, Acta Endocrinol (Copenh), 86, 146, 10.1530/acta.0.0860146 · doi:10.1530/acta.0.0860146
- Landau, 1978, Unilateral adrenalectomy and pituitary irradiation in the treatment of ACTH-dependent Cushing's disease in children and adolescents, Clin Endocrinol (Oxf), 9, 221, 10.1111/j.1365-2265.1978.tb02203.x · doi:10.1111/j.1365-2265.1978.tb02203.x
- Ernest, 1972, Adrenalectomy in Cushing's disease. A long-term follow-up, Acta Endocrinol Suppl (Copenh), 160, 3
- Tomita, 1981, Follow-up study on treatment in 27 patients with Cushing's disease: adrenalectomy, transsphenoidal adenomectomy and medical treatment, Endocrinol Jpn, 28, 197, 10.1507/endocrj1954.28.197 · doi:10.1507/endocrj1954.28.197
- Kelly, 1983, Cushing's disease treated by total adrenalectomy: long-term observations of 43 patients, Q J Med, 52, 224
- Bax, 1996, Laparoscopic bilateral adrenalectomy following failed hypophysectomy, Surg Endosc, 10, 1150, 10.1007/s004649900268 · doi:10.1007/s004649900268
- Chapuis, 1997, Bilateral laparoscopic adrenalectomy for Cushing's disease, Br J Surg, 84, 1009, 10.1002/bjs.1800840731 · doi:10.1002/bjs.1800840731
- Acosta, 1999, Laparoscopic versus open adrenalectomy in Cushing's syndrome and disease, Surgery, 126, 1111, 10.1067/msy.2099.102423 · doi:10.1067/msy.2099.102423
- Mikhail, 2006, Open versus laparoscopic simultaneous bilateral adrenalectomy, Urology, 67, 693, 10.1016/j.urology.2005.10.037 · doi:10.1016/j.urology.2005.10.037
- Bulus, 2013, Comparison of laparoscopic and open adrenalectomy, Acta Chir Belg, 113, 203, 10.1080/00015458.2013.11680912 · doi:10.1080/00015458.2013.11680912
- Munir, 2007, Nelson's syndrome, Arq Bras Endocrinol Metabol, 51, 1392, 10.1590/S0004-27302007000800026 · doi:10.1590/s0004-27302007000800026
- Kasperlik-Załuska, 2006, Nelson's syndrome – 46 years later: clinical experience with 37 patients, Zentralbl Neurochir, 67, 14, 10.1055/s-2006-921430 · doi:10.1055/s-2006-921430
- Xing, 2002, Microsurgical treatment of Nelson's syndrome, Chin Med J Engl, 115, 1150
- Kemink, 2001, Management of Nelson's syndrome: observations in fifteen patients, Clin Endocrinol (Oxf), 54, 45, 10.1046/j.1365-2265.2001.01187.x · doi:10.1046/j.1365-2265.2001.01187.x
- Wolffenbuttel, 1998, Beneficial gamma-knife radiosurgery in a patient with Nelson's syndrome, Clin Neurol Neurosurg, 100, 60, 10.1016/S0303-8467(97)00124-8 · doi:10.1016/s0303-8467(97)00124-8
- Moore, 1976, Nelson's syndrome: frequency, prognosis, and effect of prior pituitary irradiation, Ann Intern Med, 85, 731, 10.7326/0003-4819-85-6-731 · doi:10.7326/0003-4819-85-6-731
- Vik-Mo, 2009, Gamma knife stereotactic radiosurgery of Nelson syndrome, Eur J Endocrinol, 160, 143, 10.1530/EJE-08-0687 · doi:10.1530/eje-08-0687
- Gil-Cárdenas, 2007, Nelson's syndrome after bilateral adrenalectomy for Cushing's disease, Surgery, 141, 147, 10.1016/j.surg.2006.12.003 · doi:10.1016/j.surg.2006.12.003
- Kreutzer, 2009, No effect of the PPAR-γ agonist rosiglitazone on ACTH or cortisol secretion in Nelson's syndrome and Cushing's disease in vitro and in vivo, Clin Neuropathol, 28, 430
- Moyes, 2009, Treatment of Nelson's syndrome with temozolomide, Eur J Endocrinol, 160, 115, 10.1530/EJE-08-0557 · doi:10.1530/eje-08-0557
- Berselli, 1987, Effect of ketoconazole on CRH-induced ACTH and cortisol release in patients with Cushing's disease, Horm Metab Res Suppl, 16, 58
- Tabarin, 1990, Efficacy and long-term tolerance of ketoconazole in the treatment of Cushing's disease [in French], Ann Endocrinol (Paris), 51, 27
- Manavela, 2001, The association of Cushing's disease and primary empty sella turcica, Pituitary, 4, 145, 10.1023/A:1015310806063 · doi:10.1023/a:1015310806063
- Kazy, 2005, Population-based case-control study of oral ketoconazole treatment for birth outcomes, Congenit Anom (Kyoto), 45, 5, 10.1111/j.1741-4520.2005.00053.x · doi:10.1111/j.1741-4520.2005.00053.x
- Chart, 1958, New amphenone analogs as adrenocortical inhibitors, Experientia, 14, 151, 10.1007/BF02157133 · doi:10.1007/bf02157133
- Dewis, 1983, Experience with trilostane in the treatment of Cushing's syndrome, Clin Endocrinol (Oxf), 18, 533, 10.1111/j.1365-2265.1983.tb00590.x · doi:10.1111/j.1365-2265.1983.tb00590.x
- Doenicke, 1994, A comparison of two formulations for etomidate, 2-hydroxypropyl-β-cyclodextrin (HPCD) and propylene glycol, Anesth Analg, 79, 933, 10.1213/00000539-199411000-00020 · doi:10.1213/00000539-199411000-00020
- Zacharias, 1979, Venous sequelae following etomidate, Br J Anaesth, 51, 779, 10.1093/bja/51.8.779 · doi:10.1093/bja/51.8.779
- Doenicke, 1997, Haemolysis after etomidate: comparison of propylene glycol and lipid formulations, Br J Anaesth, 79, 386, 10.1093/bja/79.3.386 · doi:10.1093/bja/79.3.386
- Yorgin, 1997, Propylene glycol-induced proximal renal tubular cell injury, Am J Kidney Dis, 30, 134, 10.1016/S0272-6386(97)90577-1 · doi:10.1016/s0272-6386(97)90577-1
- Hart, 1971, Studies on the site of action of o,p'-DDD in the dog adrenal cortex. 1. Inhibition of ACTH-mediated pregnenolone synthesis, Steroids, 17, 559, 10.1016/S0039-128X(71)80157-5 · doi:10.1016/s0039-128x(71)80157-5
- Southren, 1961, Effect of o,p'DDD in a patient with Cushing's syndrome, J Clin Endocrinol Metab, 21, 201, 10.1210/jcem-21-2-201 · doi:10.1210/jcem-21-2-201
- Dickerman, 1979, Successful treatment of Cushing's disease with o,p'-DDD followed by pituitary irradiation in a 19-year-old male patient, Isr J Med Sci, 15, 455
- Takamatsu, 1981, Does mitotane reduce endogenous ACTH secretion?, N Engl J Med, 305, 957, 10.1056/NEJM198110153051617 · doi:10.1056/nejm198110153051617
- Suda, 1983, Effects of cyproheptadine, reserpine, and synthetic corticotropin-releasing factor on pituitary glands from patients with Cushing's disease, J Clin Endocrinol Metab, 56, 1094, 10.1210/jcem-56-6-1094 · doi:10.1210/jcem-56-6-1094
- Plonk, 1976, Modification of adrenal function by the anti-serotonin agent cyproheptadine, J Clin Endocrinol Metab, 42, 291, 10.1210/jcem-42-2-291 · doi:10.1210/jcem-42-2-291
- Kriegert, 1976, Letter: cyproheptadine for pituitary disorders, N Engl J Med, 295, 394, 10.1056/NEJM197608122950715 · doi:10.1056/nejm197608122950715
- Ambrosi, 1979, Lack of effect of antiserotoninergic and/or dopaminergic treatment in patients with pituitary-dependent Cushing's syndrome, Horm Metab Res, 11, 318, 10.1055/s-0028-1095778 · doi:10.1055/s-0028-1095778
- Tyrrell, 1976, More on cyproheptadine, N Engl J Med, 295, 1137, 10.1056/NEJM197611112952017 · doi:10.1056/nejm197611112952017
- Copinschi, 1977, Lack of effect of cyproheptadine in Cushing's disease and in Nelson's syndrome, Acta Endocrinol (Copenh), 312
- Koppeschaar, 1983, Sodium valproate and cyproheptadine may independently induce a remission in the same patient with Cushing's disease, Acta Endocrinol (Copenh), 104, 160, 10.1530/acta.0.1040160 · doi:10.1530/acta.0.1040160
- Tucci, 1989, Cyproheptadine may act at the pituitary in Cushing's disease: evidence from CRF stimulation, J Endocrinol Invest, 12, 197, 10.1007/BF03349961 · DOI
- Hsu, 1981, Cyproheptadine in the control of Cushing's disease, Johns Hopkins Med J, 149, 77
- Barnes, 1977, Cushing's disease: successful treatment with cyproheptadine, Lancet, 1, 1148, 10.1016/S0140-6736(77)92402-3 · doi:10.1016/s0140-6736(77)92402-3
- Ooi, 1987, Rebound elevation of cortisol following cyproheptadine withdrawal in Cushing's disease from a pituitary macroadenoma, J Endocrinol Invest, 10, 107, 10.1007/BF03347166 · doi:10.1007/bf03347166
- Middler, 1976, Letter: cyproheptadine for pituitary disorders, N Engl J Med, 295, 394, 10.1056/NEJM197608122950715 · doi:10.1056/nejm197608122950715
- Ferrari, 1977, More on cyproheptadine in Cushing's disease, N Engl J Med, 296, 576, 10.1056/NEJM197703102961022 · doi:10.1056/nejm197703102961022
- Grant, 1979, Cushing's disease presenting with growth failure: clinical remission during cyproheptadine therapy, Arch Dis Child, 54, 466, 10.1136/adc.54.6.466 · doi:10.1136/adc.54.6.466
- Pearce, 1977, Treatment of Cushing's disease with cyproheptadine, Lancet, 1, 1368, 10.1016/S0140-6736(77)92585-5 · doi:10.1016/s0140-6736(77)92585-5
- Allgrove, 1977, Cushing's disease: failure of treatment with cyproheptadine, Br Med J, 1, 686, 10.1136/bmj.1.6062.686-a · doi:10.1136/bmj.1.6062.686-a
- D'Ercole, 1977, Treatment of Cushing disease in childhood with cyproheptadine, J Pediatr, 90, 834, 10.1016/S0022-3476(77)81265-1 · doi:10.1016/s0022-3476(77)81265-1
- Kritzler, 1983, Sodium valproate and corticotropin suppression in the child treated for seizures, J Pediatr, 102, 142, 10.1016/S0022-3476(83)80313-8 · doi:10.1016/s0022-3476(83)80313-8
- Koppeschaar, 1982, Sodium valproate and heterogeneity of pituitary dependent Cushing's syndrome, Lancet, 1, 1253, 10.1016/S0140-6736(82)92383-2 · doi:10.1016/s0140-6736(82)92383-2
- Koppeschaar, 1984, Successful treatment with sodium valproate of a patient with Cushing's disease and gross enlargement of the pituitary, Acta Endocrinol (Copenh), 107, 471, 10.1530/acta.0.1070471 · doi:10.1530/acta.0.1070471
- Cavagnini, 1984, Sodium valproate in Cushing's disease, Lancet, 2, 162, 10.1016/S0140-6736(84)91074-2 · doi:10.1016/s0140-6736(84)91074-2
- Ambrosi, 1983, Effects of sodium-valproate administration on plasma ACTH levels in patients with ACTH hypersecretion, J Endocrinol Invest, 6, 305, 10.1007/BF03347595 · doi:10.1007/bf03347595
- Reincke, 1988, The effect of sodium valproate in Cushing's disease, Nelson's syndrome and Addison's disease, Klin Wochenschr, 66, 686, 10.1007/BF01726927 · doi:10.1007/bf01726927
- Loli, 1984, Lack of ACTH lowering effect of sodium valproate in patients with ACTH hypersecretion, J Endocrinol Invest, 7, 93, 10.1007/BF03348396 · doi:10.1007/bf03348396
- Allolio, 1982, Valproate in Cushing's syndrome, Lancet, 1, 171, 10.1016/S0140-6736(82)90422-6 · doi:10.1016/s0140-6736(82)90422-6
- Koppeschaar, 1986, Response to neurotransmitter modulating drugs in patients with Cushing's disease, Clin Endocrinol (Oxf), 25, 661, 10.1111/j.1365-2265.1986.tb03621.x · doi:10.1111/j.1365-2265.1986.tb03621.x
- Beckers, 1990, Cyclical Cushing's disease and its successful control under sodium valproate, J Endocrinol Invest, 13, 923, 10.1007/BF03349657 · doi:10.1007/bf03349657
- Nussey, 1988, The combined use of sodium valproate and metyrapone in the treatment of Cushing's syndrome, Clin Endocrinol (Oxf), 28, 373, 10.1111/j.1365-2265.1988.tb03668.x · doi:10.1111/j.1365-2265.1988.tb03668.x
- Ferone, 2007, Preclinical and clinical experiences with the role of dopamine receptors in the treatment of pituitary adenomas, Eur J Endocrinol, 156, S37, 10.1530/eje.1.02351 · doi:10.1530/eje.1.02351
- Nobels, 2000, Long-term treatment with the dopamine agonist quinagolide of patients with clinically non-functioning pituitary adenoma, Eur J Endocrinol, 143, 615, 10.1530/eje.0.1430615 · doi:10.1530/eje.0.1430615
- Greenman, 2005, Postoperative treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists decreases tumour remnant growth, Clin Endocrinol (Oxf), 63, 39, 10.1111/j.1365-2265.2005.02295.x · doi:10.1111/j.1365-2265.2005.02295.x
- Pirker, 1996, Dopamine D2 receptor imaging in pituitary adenomas using iodine-123-epidepride and SPECT, J Nucl Med, 37, 1931
- Adams, 1981, Bromocriptine suppresses ACTH secretion from human pituitary tumour cells in culture by a dopaminergic mechanism, Clin Endocrinol (Oxf), 15, 479, 10.1111/j.1365-2265.1981.tb00691.x · doi:10.1111/j.1365-2265.1981.tb00691.x
- Yin, 1994, Induction of apoptosis in murine ACTH-secreting pituitary adenoma cells by bromocriptine, FEBS Lett, 339, 73, 10.1016/0014-5793(94)80387-0 · DOI
- Lamberts, 1977, The role of dopaminergic depletion in the pathogenesis of Cushing's disease and the possible consequences for medical therapy, Clin Endocrinol (Oxf), 7, 185, 10.1111/j.1365-2265.1977.tb01314.x · doi:10.1111/j.1365-2265.1977.tb01314.x
- Adachi, 1996, Cyclic Cushing's disease in long-term remission with a daily low dose of bromocriptine, Intern Med, 35, 207, 10.2169/internalmedicine.35.207 · doi:10.2169/internalmedicine.35.207
- McNicol, 1986, A study of corticotroph adenomas in Cushing's disease: no evidence of intermediate lobe origin, Clin Endocrinol (Oxf), 24, 715, 10.1111/j.1365-2265.1986.tb01668.x · doi:10.1111/j.1365-2265.1986.tb01668.x
- Meij, 2000, Double pituitary lesions in three patients with Cushing's disease, Pituitary, 3, 159, 10.1023/A:1011499609096 · doi:10.1023/a:1011499609096
- Nielsen, 2001, Expression of somatostatin receptors on human pituitary adenomas in vivo and ex vivo, J Endocrinol Invest, 24, 430, 10.1007/BF03351043 · doi:10.1007/bf03351043
- Pivonello, 2003, Role of somatostatin analogs in the management of non-functioning neuroendocrine tumors, J Endocrinol Invest, 26, 82
- Invitti, 1991, Effect of sandostatin on CRF-stimulated secretion of ACTH, β-lipotropin and β-endorphin, Horm Metab Res, 23, 233, 10.1055/s-2007-1003660 · doi:10.1055/s-2007-1003660
- Julesz, 1980, Effects of somatostatin and bromocryptine on the plasma ACTH level in bilaterally adrenalectomized patients with Cushing's disease, Endokrinologie, 76, 68
- Kraus, 1999, Regulation of mouse somatostatin receptor type 2 gene expression by glucocorticoids, FEBS Lett, 459, 200, 10.1016/S0014-5793(99)01236-3 · doi:10.1016/s0014-5793(99)01236-3
- Ruan, 2006, SOM230 inhibits insulin-like growth factor-I action in mammary gland development by pituitary independent mechanism: mediated through somatostatin subtype receptor 3?, Mol Endocrinol, 20, 426, 10.1210/me.2005-0283 · DOI
- Lacroix, 2012, Medical treatment of Cushing's disease with pasireotide, Eur J Endocrinol, 8, 99, 10.17925/EE.2012.08.02.99 · doi:10.17925/ee.2012.08.02.99
- Cukier, 2009, Significant response to pasireotide (SOM230) in the treatment of a patient with persistent, refractory Cushing's disease, Clin Endocrinol (Oxf), 71, 305, 10.1111/j.1365-2265.2008.03486.x · doi:10.1111/j.1365-2265.2008.03486.x
- Culler, 2011, Somatostatin-dopamine chimeras: a novel approach to treatment of neuroendocrine tumors, Horm Metab Res, 43, 854, 10.1055/s-0031-1287769 · doi:10.1055/s-0031-1287769
- Colao, 2010, Pituitary carcinomas, Front Horm Res, 38, 94, 10.1159/000318499 · doi:10.1159/000318499
Cited by
Consensus on diagnosis and management of Cushing's disease: a guideline update
Fleseriu, M., Auchus, R., Bancos, I., Ben-Shlomo, A., Bertherat, J., Biermasz, N. R., Boguszewski, C. L., Bronstein, M. D., Buchfelder, M., Carmichael, J. D., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00235-7 · Cited by 953
Self-citationComplications of Cushing's syndrome: state of the art
Pivonello, R., Isidori, A. M., De Martino, M. C., Newell-Price, J., Biller, B. M. K., & Colao, A. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00086-3 · Cited by 641
Self-citationReincke, M., & Fleseriu, M. (2023) · JAMA · doi:10.1001/jama.2023.11305 · Cited by 256
Pivonello, R., Fleseriu, M., Newell-Price, J., Bertagna, X., Findling, J., Shimatsu, A., Gu, F., Auchus, R., Leelawattana, R., Lee, E. J., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30240-0 · Cited by 222
Self-citationClayton, R. N., Jones, P. W., Reulen, R. C., Stewart, P. M., Hassan-Smith, Z. K., Ntali, G., Karavitaki, N., Dekkers, O. M., Pereira, A. M., Bolland, M., et al. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30005-5 · Cited by 208
Metadata
- Authors
- Pivonello, R., De Leo, M., Cozzolino, A., & Colao, A.
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2015-08-01
- Volume
- 36
- Issue
- 4
- Pages
- 385-486
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W1910274646
- Cited by
- 465
- References
- 641
- FWCI
- 27.09
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.